Form 4: Versant Venture Capital Reduces Significant Stake in LENZ Therapeutics

Sentiment:

Insider Transaction Report 14 July 2025 4:50 PM

Versant Venture Capital entities, a 10% owner and director of LENZ Therapeutics, Inc., reported the sale of 191,376 shares of common stock for $34 per share.

Worse than expectedThe sale of a substantial number of shares by a 10% owner and director, such as Versant Venture Capital, is generally viewed as a negative signal by investors, potentially indicating a less favorable outlook from a key insider.

Summary

Versant Venture Capital VI, L.P., along with related entities Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., and Versant Ventures VII GP-GP, LLC, collectively identified as 10% owners and directors, reported a transaction.
On July 10, 2025, 191,376 shares of LENZ Therapeutics, Inc. common stock were disposed of at a price of $34 per share.
Following the reported transaction, Versant Venture Capital VI, L.P. directly holds 1,575,899 shares.
Versant Venture Capital VII, L.P. indirectly holds 1,047,912 shares.
Versant Vantage II, L.P. indirectly holds 842,162 shares.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant insider sale by a major investor and director, which can be interpreted as a lack of confidence or a strategic exit from a portion of their holdings.

Negatives

A significant sale of 191,376 shares by a 10% owner and director, Versant Venture Capital, could be perceived negatively by the market as it may signal a lack of confidence or a strategic divestment.

Future Outlook

Industry Context

This filing reports a specific insider transaction and does not provide broader industry context or trends. It reflects a change in ownership by a significant institutional investor in a biotechnology company.

Related Party Transactions

The reported transaction involves the sale of common stock by Versant Venture Capital entities, which are identified as a 10% owner and director of LENZ Therapeutics, Inc., making this an insider or related-party transaction.

Stakeholder Impact

Shareholders may react negatively to the news of a significant sale by a major institutional investor and director, potentially leading to downward pressure on the stock price.

Key Dates

Date	Description
07/10/2025	Date of the reported transaction (sale of common stock).
07/14/2025	Date the Form 4 filing was signed by the reporting person.

Keywords

LENZ Therapeutics, Versant Venture Capital, Form 4, insider trading, stock sale, beneficial ownership, common stock, biotechnology, pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.